Corteva (CTVA) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
9 Jul, 2026Executive summary
Third quarter 2024 results were in line with expectations, with net sales down 10% year-over-year to $2.33B and an operating loss, reflecting challenging dynamics in Latin America and competitive pricing pressures.
Crop Protection delivered earnings and margin growth, benefiting from demand for differentiated technology, initial deflation benefits, and volume gains in new products and biologicals.
Seed business showed strong year-to-date performance, with pricing gains and share growth in North America, but faced significant declines in Latin America and a Q3 EBITDA loss.
Over $400 million in controllable cost savings targeted for 2024, supporting margin stability despite lower revenue expectations.
2025 is expected to return to double-digit operating EBITDA growth and margin expansion, driven by cost improvements, innovation, and a robust product pipeline.
Financial highlights
Q3 2024 net sales declined 10% year-over-year to $2.33B; YTD net sales down 4% to $12.93B.
Q3 2024 operating EBITDA was $(100)M, with a margin of (4.3)% and a net loss from continuing operations of $519M; YTD operating EBITDA was $2.85B, down 5% year-over-year, with a 22% margin.
Q3 2024 GAAP EPS was $(0.76); YTD GAAP EPS was $1.29, down 21% year-over-year.
Full-year 2024 net sales guidance updated to $17.0–$17.2B, down 1% at midpoint; operating EBITDA guidance $3.35–$3.45B, up 1% at midpoint.
Operating EPS expected at $2.50–$2.60, down 5% year-over-year; free cash flow guidance reaffirmed at $1.5–$2.0B.
Outlook and guidance
2024 full-year EBITDA margin expected at ~20%, with free cash flow conversion rate of 45%–50%.
2025 preliminary outlook: net sales $17.3–$17.7B, operating EBITDA $3.6–$4.0B, with double-digit EBITDA growth and margin expansion.
Seed pricing expected to grow low single digits; crop protection industry expected to be flat in 2025.
$400M in cost improvements anticipated for 2025, with continued benefits from deflation and productivity.
Guidance excludes impacts from extreme weather, major operational disruptions, or further macroeconomic shocks.
Latest events from Corteva
- Seed strength and margin gains offset Crop Protection headwinds; 2024 outlook trimmed.CTVA
Q2 20248 Jul 2026 - 2025 guidance targets 10% EBITDA growth and margin expansion amid strong segment momentum.CTVA
Q4 20248 Jul 2026 - EU gene editing approval and innovation in seeds and AI set the stage for long-term growth.CTVA
Wolfe Research 3rd Annual Materials of the Future Conference 202617 Jun 2026 - Six growth platforms and innovation target $4.4B EBITDA, 23–25% margins, and $4.5B returns by 2027.CTVA
Investor Day 202426 May 2026 - Separation on track as innovation and licensing drive growth in seed and crop protection.CTVA
21st Annual Global Farm to Market Conference14 May 2026 - Q1 2026 delivered double-digit sales and EBITDA growth, margin gains, and strategic progress.CTVA
Q1 20266 May 2026 - Strong financials, leadership changes, and all proposals approved amid strategic separation plans.CTVA
AGM 202629 Apr 2026 - 2025 saw record EBITDA and cash flow; 2026 outlook targets 7% EBITDA growth and separation.CTVA
Q4 202517 Apr 2026 - Annual meeting to vote on directors, executive pay, and auditor ratification, all board-backed.CTVA
Proxy filing19 Mar 2026